All Posts: lung cancer
-
The Power of Lombardi Care
Jaime Posada was diagnosed with stage 4 lung cancer and given two to six months to live. That was in 2017, before he came to Georgetown Lombardi. Hear Posada’s compelling story.
Category: Special Stories
-
Georgetown Lombardi Faculty Members Aim To Improve Lung Cancer Screening and Smoking Cessation Rates by Focusing on Equity in Care
Kathryn Taylor, PhD, professor of oncology, believes she can have no greater impact on reducing the burden of cancer than by focusing on the harms of tobacco use. The work she co-leads with Randi Williams, PhD, assistant professor of oncology, as part of the Lung Screening, Tobacco, and Health (LSTH) research lab at Georgetown University’s Lombardi Comprehensive Cancer Center is especially impactful on underserved communities, who are often the target of tobacco product marketing.
Category: Lombardi Stories
-
Routine Lung Screening Spots Aggressive Cancer Early, Allows Successful Treatment
The detection of an aggressive form of lung cancer in a patient treated by experts at Georgetown University’s Lombardi Comprehensive Cancer Center demonstrates the importance of routine screenings and a strong relationship between patients and their primary care physicians.
Category: Lombardi Stories
-
Intensive Telephone-Based Cessation Counseling Results in Improved Smoking Quit Rates
WASHINGTON (July 12, 2022) — Offering intensive, weekly telephone-based cessation counseling along with nicotine replacement for people who smoke and who were undergoing screening for lung cancer resulted in over a twofold greater cigarette quit rate compared to people who received minimal counseling and nicotine replacement, according to results of a national, randomized trial conducted […]
Category: News Release
-
Georgetown Lombardi Oncologists Encourage Patients to Keep Up with Cancer Screenings
(November 20, 2020) — If you’re due for a routine cancer screening test, you should contact your doctor to find out if it can be safely deferred until the risk of COVID-19 goes down. In contrast, if you have symptoms that could be a sign of cancer, don’t delay and don’t let the pandemic discourage […]
Category: Lombardi Stories
-
FDA Approves Lung Cancer Drug Supported by Georgetown Lombardi Research
(September 14, 2020) — Julie Shanholtz was having an uneventful summer in 2017 working full time with the same employer she’d had for the past 30 years when she developed an “odd cough” that quickly became severe, but no other symptoms. “I had always been very active and healthy — and didn’t smoke,” the 54-year-old […]
Category: Lombardi Stories
-
Adding Smoking Cessation to Lung Cancer Screening Can Reduce Mortality by 14%
WASHINGTON (March 9, 2020) — Including smoking cessation with existing lung cancer screening efforts would reduce lung cancer mortality by 14 percent and increase life-years gained by 81 percent compared with screening alone, according to a study led by researchers at the University of Michigan and Georgetown Lombardi Comprehensive Cancer Center. The study is published […]
Category: News Release
-
Nearly One-Quarter of Completed Lung Cancer Clinical Trial Results Are Not Published
WASHINGTON (November 6, 2019) — Despite the lengthy time and money commitments that are required to conduct clinical trials, a new analysis has found that up to one-fourth of completed lung cancer clinical trial results are not published, thereby depriving patients, the research community and the public of a complete picture of the current state of […]
Category: News Release
-
When Enough is Enough! Smoking Cessation at Georgetown Lombardi
Two programs offered through Georgetown Lombardi and MedStar Georgetown University Hospital offer options to help smokers understand their risk for lung cancer and quit smoking, both before and after they’ve received a cancer diagnosis.
Category: Lombardi Stories
-
Rare but Important Gene Target Found in Many Tumor Types, Suggesting New Therapy Possible
A consortium of researchers led by Georgetown Lombardi Comprehensive Cancer Center investigators have completed the largest analysis of a new gene fusion they believe is responsible for development of a wide spectrum of cancer types.
Category: News Release